Skip to content

Cerus CERS Stock-Based Comp

Stock-Based Comp at other companies

CorMedix logo
CorMedixCRMD
$4.58M+30.9%
Haemonetics logo
HaemoneticsHAE
$9.13M+31.6%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$14.52M+5.2%
QuidelOrtho Corporation logo
QuidelOrtho CorporationQDEL
$10.7M-7.8%
ADMA Biologics logo
ADMA BiologicsADMA
$6.33M+36.9%
Paysign logo
PaysignPAYS
$1.28M+91.0%

Other financials

Income statement

See full
Revenue$53.7M+24.1%
Operating income-$354.0K+94.0%
Net income-$1.6M+78.7%
EPS (diluted)-$0.01+75.0%

Balance sheet

See full
Cash & equivalents$27.9M+43.0%
Total debt$45.0M-43.3%
Total equity$67.6M+21.7%
Total assets$222.9M+7.8%

Cash flow

See full
Operating cash flow-$3.0M-261%
CapEx$233.0K+108%
Free cash flow-$3.3M-243%

Valuation

See full
Market cap$573.06M+124%
Enterprise value$590.17M+86.7%
P/S2.9×-1.0×

Profitability

See full
Gross margin64%
Operating margin-6.2%-2.1pp
Net margin-9.8%-2.8pp
FCF margin3.5%+1.9pp

Returns & leverage

See full
Return on equity-15.5%-5.6pp
Debt / equity0.7×-0.8×
Current ratio1.6×-0.7×

Where this comes from

Reported directly by Cerus in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Cerus’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cerus's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cerus's stock-based comp?
Cerus (CERS) reported stock-based comp of $4.9M in Q1 2026.
How has Cerus's stock-based comp changed year-over-year?
Cerus's stock-based comp decreased by 26.1% year-over-year, from $6.64M to $4.9M.
What is the long-term trend for Cerus's stock-based comp?
Over 4 years (2021 to 2025), Cerus's stock-based comp has grown at a -0.8% compound annual growth rate (CAGR), from $23.57M to $22.87M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.